Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasper Dingemanse

Showing results (151-160 of 238) with videos related to

Pageof 24
Sort By:
Pharmacological Research|August 8, 2020
Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditionsChristine Huynh, Jasper Dingemanse, Henriette E Meyer Zu Schwabedissen, et al.
Basic & Clinical Pharmacology & Toxicology|October 8, 2014
Effect of ponesimod, a selective S1P1 receptor modulator, on the QT interval in healthy individualsMatthias Hoch, Borje Darpo, Patrick Brossard, et al.
Clinical Drug Investigation|July 31, 2021
Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT AnalysisUta Schilling, Andrea Henrich, Clemens Muehlan, et al.
Drug Design, Development and Therapy|January 19, 2017
Effects of multiple-dose ponesimod, a selective S1P<sub>1</sub> receptor modulator, on lymphocyte subsets in healthy humansStipo Jurcevic, Pierre-Eric Juif, Colleen Hamid, et al.
Journal of Clinical Pharmacology|August 26, 2016
Mitigation of Initial Cardiodynamic Effects of the S1P<sub>1</sub> Receptor Modulator Ponesimod Using a Novel Up-Titration RegimenPierre-Eric Juif, Matthias Hoch, Andrea Vaclavkova, et al.
Expert Opinion on Drug Safety|November 23, 2013
Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertensionJasper Dingemanse, Patricia N Sidharta, Willis C Maddrey, et al.
Clinical Pharmacology and Therapeutics|April 17, 2002
In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburidePaul L M van Giersbergen, Alexander Treiber, Martine Clozel, et al.
European Journal of Clinical Pharmacology|October 18, 2014
Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2 antagonistMartine Gehin, Patricia N Sidharta, Carmela Gnerre, et al.
Clinical and Translational Science|November 3, 2020
Assessment of Target Engagement in a First-in-Human Trial with Sinbaglustat, an Iminosugar to Treat Lysosomal Storage DisordersMartine Gehin, Meggane Melchior, Richard W D Welford, et al.
Journal of Clinical Pharmacology|December 28, 2020
Effect of Renal Function Impairment on the Pharmacokinetics, Safety, and Tolerability of the Iminosugar SinbaglustatMeggane Melchior, Jasper Dingemanse, Abir Alatrach, et al.
Pageof 24

Showing results (151-160 of 238) with videos related to

Sort By:
Pageof 24
Pharmacological Research|August 8, 2020
Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditionsChristine Huynh, Jasper Dingemanse, Henriette E Meyer Zu Schwabedissen, et al.
Basic & Clinical Pharmacology & Toxicology|October 8, 2014
Effect of ponesimod, a selective S1P1 receptor modulator, on the QT interval in healthy individualsMatthias Hoch, Borje Darpo, Patrick Brossard, et al.
Clinical Drug Investigation|July 31, 2021
Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT AnalysisUta Schilling, Andrea Henrich, Clemens Muehlan, et al.
Drug Design, Development and Therapy|January 19, 2017
Effects of multiple-dose ponesimod, a selective S1P<sub>1</sub> receptor modulator, on lymphocyte subsets in healthy humansStipo Jurcevic, Pierre-Eric Juif, Colleen Hamid, et al.
Journal of Clinical Pharmacology|August 26, 2016
Mitigation of Initial Cardiodynamic Effects of the S1P<sub>1</sub> Receptor Modulator Ponesimod Using a Novel Up-Titration RegimenPierre-Eric Juif, Matthias Hoch, Andrea Vaclavkova, et al.
Expert Opinion on Drug Safety|November 23, 2013
Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertensionJasper Dingemanse, Patricia N Sidharta, Willis C Maddrey, et al.
Clinical Pharmacology and Therapeutics|April 17, 2002
In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburidePaul L M van Giersbergen, Alexander Treiber, Martine Clozel, et al.
European Journal of Clinical Pharmacology|October 18, 2014
Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2 antagonistMartine Gehin, Patricia N Sidharta, Carmela Gnerre, et al.
Clinical and Translational Science|November 3, 2020
Assessment of Target Engagement in a First-in-Human Trial with Sinbaglustat, an Iminosugar to Treat Lysosomal Storage DisordersMartine Gehin, Meggane Melchior, Richard W D Welford, et al.
Journal of Clinical Pharmacology|December 28, 2020
Effect of Renal Function Impairment on the Pharmacokinetics, Safety, and Tolerability of the Iminosugar SinbaglustatMeggane Melchior, Jasper Dingemanse, Abir Alatrach, et al.
Pageof 24